Drug Trial Radar · NCT01546038
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Mar 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Jun 27, 2012
Primary completion
Jan 3, 2017
Study completion Mar 4, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.
Conditions
- Acute Myeloid Leukemia
Interventions
PF-04449913Drug
PF-04449913 administered orally and continuously for 28-days.
Low dose ARA-C (LDAC)Drug
Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
PF-04449913Drug
PF-04449913 administered orally and continuously for 28 days.
DecitabineDrug
Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
PF-04449913Drug
PF-04449913 administered orally and continuously for 28 days
DaunorubicinDrug
Daunorubicin given using 60 mg/m2 for 3-days
CytarabineDrug
Cytarabine 100 mg/m2 on days 1 through 7
PF-04449913Drug
PF-04449913 administered orally and continuously for 28 days
DaunorubicinDrug
Daunorubicin given using 60 mg/m2 for 3-days
CytarabineDrug
Cytarabine 100 mg/m2 on days 1 through 7
PF-04449913Drug
PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
Low dose ARA-C (LDAC)Drug
Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1BTime frame: Arms A and B: Cycle 1, Day 1 to Day 28; Arm C: Cycle 1, Day -3 to Day 21 or to Day 28 depending on when the next chemotherapy cycle was started
- Percentage of Participants With Complete Response (CR) at Phase 2 FitTime frame: 4 years
- Overall Survival (OS) at Phase 2 UnfitTime frame: Randomization to Follow-up (4 years)
Locations
81 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
UC San Diego Moores Cancer Center - Investigational Drug Services
La Jolla, California
UC San Diego Medical Center - La Jolla
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
Keck Hospital of USC
Los Angeles, California
LAC & USC Medical Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Ronald Reagan UCLA Medical Center Drug Information Center
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Drug lnformation/lnvestigational Drugs
Los Angeles, California
UCLA Hematology/Oncology Clinic
Los Angeles, California
UC San Diego Medical Center - Hillcrest
San Diego, California
University of Colorado Denver
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
H.Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Emory University Hospital
Atlanta, Georgia
Investigational Drug Service, Emory University Clinic
Atlanta, Georgia
The Emory Clinic
Atlanta, Georgia
Winship Cancer Institute, Emory University
Atlanta, Georgia
Northwestern Medical Faculty Foundation
Chicago, Illinois
Northwestern Medicine Developmental Therapeutics Institute
Chicago, Illinois
Northwestern Memorial Hospital
Chicago, Illinois
The University of Chicago Medical Center
Chicago, Illinois
The University of Chicago's Medical Center
Chicago, Illinois
University of Kansas Clinical Research Center
Fairway, Kansas
University of Kansas Hospital
Kansas City, Kansas
University of Kansas Cancer Center and Medical Pavilion
Westwood, Kansas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center Clinical Trials Office
Ann Arbor, Michigan
University of Michigan Health System
Ann Arbor, Michigan
Siteman Cancer Center - West County
Creve Coeur, Missouri
Barnes Jewish Hospital North Campus
St Louis, Missouri
Barnes-Jewish Hospital
St Louis, Missouri
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.